(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 71.6% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 21.94%.
Mesoblast's revenue in 2026 is $65,384,000.On average, 6 Wall Street analysts forecast MESO's revenue for 2026 to be $164,994,339,091, with the lowest MESO revenue forecast at $151,787,060,874, and the highest MESO revenue forecast at $196,318,137,477. On average, 7 Wall Street analysts forecast MESO's revenue for 2027 to be $228,853,139,914, with the lowest MESO revenue forecast at $129,624,603,769, and the highest MESO revenue forecast at $291,565,162,433.
In 2028, MESO is forecast to generate $455,734,851,958 in revenue, with the lowest revenue forecast at $226,830,171,446 and the highest revenue forecast at $746,423,824,227.